Publications by authors named "Sang C Oh"

Claim this Profile
P
Predictors of overall survival in advanced biliary tract cancer in the phase 3 TOPAZ-1 study.
Aiwu R He, Mohamed Bouattour, Vineet G Gupta, Ludovic Evesque, David B Zhen, Joon Oh Park, Sang Cheul Oh, Taroh Satoh, Do-Youn Oh

Hepatol Commun· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.
Keun-Wook Lee, Li-Yuan Bai, Minkyu Jung, Jieer Ying, Young-Hyuck Im, Do-Youn Oh, Sang Cheul Oh

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW.
Keun-Wook Lee, Sang Cheul Oh, Jong Gwang Kim, Sun Jin Sym, Byoung Yong Shim, Do-Youn Oh

Cancer Res Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trans cinnamaldehyde enhances TRAIL induced apoptosis through ER stress mediated upregulation of DR5 in colorectal cancer cells.
Dae Yeong Kim, Bu Gyeom Kim, Hye Mi Yun, Ok Hyeon Kim, Sanghee Kang, Sang Cheul Oh

Sci Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.
Changhoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, Robin Kate Kelley, Arndt Vogel, Sang Cheul Oh, Joon Oh Park

J Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic Anticancer Effects of Fibroblast Growth Factor Receptor Inhibitor and Cannabidiol in Colorectal Cancer.
Yeonuk Ju, Bu Gyeom Kim, Jeong-An Gim, Jun Woo Bong, Chin Ock Cheong, Sang Cheul Oh

Nutrients· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).
Yoon-Koo Kang, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Sun Young Rha, Sung Yong Oh, So Yeon Oh

Cancer Res Treat· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraperitoneal paclitaxel with systemic S-1 plus oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis: A single-arm, multicenter phase II clinical trial.
Won Jun Seo, Dong-Wook Kim, Chang Min Lee, Ji Yeon Park, You-Jin Jang, Sang Chul Oh

Eur J Surg Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS-STING Pathway in Triple-Negative Breast Cancer Cells.
Bu Gyeom Kim, Bo Ram Kim, Dae Yeong Kim, Woo Young Kim, Sanghee Kang, Sang Cheul Oh

Cancer Immunol Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Narikazu Boku, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Kensei Yamaguchi, Do-Youn Oh, Sang Cheul Oh

Gastric Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis.
Yoon-Koo Kang, Shukui Qin, Keun-Wook Lee, Sang Cheul Oh, In-Ho Kim

Gastric Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Yoon-Koo Kang, Hyung-Don Kim, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Sang Cheul Oh, Oh Jeong, ChoHyun Park, Sung Hoon Noh

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daunorubicin induces GLI1‑dependent apoptosis in colorectal cancer cell lines.
Bo Ram Kim, Dae Yeong Kim, Na Ly Tran, Bu Gyeom Kim, Sun Il Lee, Sang Cheul Oh

Int J Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Shukui Qin, Kensei Yamaguchi, Sang Cheul Oh

Gastric Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Yoon-Koo Kang, Min-Hee Ryu, Maria Di Bartolomeo, Ian Chau, Harry Yoon, Sang Chul Oh

Gastric Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically conserved genomic subtypes of gastric adenocarcinoma.
Yun Seong Jeong, Young-Gyu Eun, Sung Hwan Lee, Sang-Hee Kang, Sun Young Yim, Joo Kyung Noh, Bo Hwa Sohn, Sang Cheul Oh

Mol Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger, Sang Cheul Oh, Mok Oh

Nat Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial.
Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Sang Cheul Oh, Cindy Oh

EClinicalMedicine· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Daniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, Keun-Wook Lee, Matthew Ch Ng, Sang Cheul Oh, Do-Youn Oh

Oncology (Williston Park)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perception and safety analysis of COVID-19 vaccination in cancer patients: A multicenter, real-world study.
Kyoungmin Lee, In Hae Park, Sang Cheul Oh, Jae Hong Seo, Min Ji Jeon, Soohyeon Lee

Cancer Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Manish A Shah, Takayuki Yoshino, Niall C Tebbutt, Axel Grothey, Josep Tabernero, Sang Cheul Oh, Johanna Bendell

Clin Colorectal Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.
Hyung-Don Kim, Jong Seok Lee, Young Soo Park, Jeong Hwan Yook, Sung Hoon Noh, Sang Cheul Oh

Gastric Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, Sang Cheul Oh

Lancet Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AF8c, a Multi-Kinase Inhibitor Induces Apoptosis by Activating DR5/Nrf2 via ROS in Colorectal Cancer Cells.
Soyeon Jeong, Ahmed K Farag, Hye Kyeong Yun, Yoon A Jeong, Dae Yeong Kim, Eun Joo Roh, Sang Cheul Oh

Cancers (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Yoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Kohei Shitara, Sung-Yong Oh

Lancet Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis